Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms

Diagn Microbiol Infect Dis. 2020 Jul;97(3):115054. doi: 10.1016/j.diagmicrobio.2020.115054. Epub 2020 Apr 2.

Abstract

Omadacycline and tigecycline MIC90 values were 2 μg/mL and 0.25 μg/mL, respectively, against Staphylococcus aureus carrying tet(M), whereas the minocycline, tetracycline, and doxycycline values were > 8 μg/mL. Similarly, omadacycline and tigecycline remained active against Enterococcus faecalis and Streptococcus pneumoniae harboring tet(L)and/or tet(M)(MIC90, 0.06-0.25 μg/mL), whereas other tetracyclines were inactive (MIC90, >8 μg/mL). Omadacycline and tigecycline remained more potent than minocycline, tetracycline, and doxycycline against Enterobacteriaceae carrying tet. This study demonstrates the effectiveness of modern tetracyclines, omadacycline, and tigecycline against isolates with tetracycline resistance genes.

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bacteria / drug effects
  • Bacteria / genetics
  • Bacteria / isolation & purification
  • Bacterial Proteins / genetics
  • Genotype
  • Humans
  • Microbial Sensitivity Tests
  • Tetracycline Resistance / drug effects*
  • Tetracycline Resistance / genetics
  • Tetracyclines / pharmacology*
  • Tigecycline / pharmacology

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Tetracyclines
  • omadacycline
  • Tigecycline